These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
489 related articles for article (PubMed ID: 21262381)
41. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug? Cao Y Int J Dev Biol; 2011; 55(4-5):557-62. PubMed ID: 21858776 [TBL] [Abstract][Full Text] [Related]
42. Anti-angiogenesis in cancer therapy: Hercules and hydra. Bellou S; Pentheroudakis G; Murphy C; Fotsis T Cancer Lett; 2013 Sep; 338(2):219-28. PubMed ID: 23707856 [TBL] [Abstract][Full Text] [Related]
43. Unraveling galectin-1 as a novel therapeutic target for cancer. Astorgues-Xerri L; Riveiro ME; Tijeras-Raballand A; Serova M; Neuzillet C; Albert S; Raymond E; Faivre S Cancer Treat Rev; 2014 Mar; 40(2):307-19. PubMed ID: 23953240 [TBL] [Abstract][Full Text] [Related]
44. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Limaverde-Sousa G; Sternberg C; Ferreira CG Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358 [TBL] [Abstract][Full Text] [Related]
45. Molecular targets in the discovery and development of novel antimetastatic agents: current progress and future prospects. Wong MS; Sidik SM; Mahmud R; Stanslas J Clin Exp Pharmacol Physiol; 2013 May; 40(5):307-19. PubMed ID: 23534409 [TBL] [Abstract][Full Text] [Related]
47. Vascular endothelial growth factor: biology and therapeutic applications. Ho QT; Kuo CJ Int J Biochem Cell Biol; 2007; 39(7-8):1349-57. PubMed ID: 17537667 [TBL] [Abstract][Full Text] [Related]
48. Targeting Rho GTPase signaling for cancer therapy. Mardilovich K; Olson MF; Baugh M Future Oncol; 2012 Feb; 8(2):165-77. PubMed ID: 22335581 [TBL] [Abstract][Full Text] [Related]
49. Angiogenesis in cancer - general pathways and their therapeutic implications. Dimova I; Popivanov G; Djonov V J BUON; 2014; 19(1):15-21. PubMed ID: 24659637 [TBL] [Abstract][Full Text] [Related]
50. Targeting the VEGF signaling pathway in cancer therapy. Waldner MJ; Neurath MF Expert Opin Ther Targets; 2012 Jan; 16(1):5-13. PubMed ID: 22239434 [TBL] [Abstract][Full Text] [Related]
51. Synopsis of angiogenesis inhibitors in oncology. Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576 [TBL] [Abstract][Full Text] [Related]
52. The VEGF pathway in lung cancer. Alevizakos M; Kaltsas S; Syrigos KN Cancer Chemother Pharmacol; 2013 Dec; 72(6):1169-81. PubMed ID: 24085262 [TBL] [Abstract][Full Text] [Related]
58. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Niu G; Chen X Curr Drug Targets; 2010 Aug; 11(8):1000-17. PubMed ID: 20426765 [TBL] [Abstract][Full Text] [Related]
59. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling. Simon T; Gagliano T; Giamas G Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910 [TBL] [Abstract][Full Text] [Related]
60. The critical role of vascular endothelial growth factor in tumor angiogenesis. Amini A; Masoumi Moghaddam S; Morris DL; Pourgholami MH Curr Cancer Drug Targets; 2012 Jan; 12(1):23-43. PubMed ID: 22111836 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]